Tenaya Therapeutics, Inc.
corporate_fare Company Profile
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for TNYA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for TNYA spans 8-K, PRE 14A, 10-Q, DEFA14A.
Recent high-impact activity:
- Tenaya Q3 Loss Beats Estimates; $66.8M Cash Runs Into Q4 2027
- Tenaya Posts $18.9M Q3 Loss, Cash Through Q4 2027, Year-End Data on TN-201/TN-401
- Tenaya Seeks Stockholder Approval for 1-for-10 to 1-for-25 Reverse Split to Avoid Nasdaq Delisting
- FDA Grants RMAT Designation to Tenaya's TN-401 Gene Therapy for PKP2-ARVC
- Tenaya Q2 Loss Widens on $21.8M Impairment, Cash Runway Extended to Q3 2027
Financial Snapshot
Short Interest & Short Volume
8.71 days to coverFINRA reported short interest of 23,407,267 shares in TNYA as of the October 30, 2026 settlement, a 4.0% increase from the prior period — about 8.7 days to cover at its recent average daily volume. On November 20, 2026, 39.7% of TNYA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.